I am working on a project that seeks to understand how improved access to data (excluding pre-clinical data) from different health system stakeholders could drive innovation in the bio-pharmaceutical sector and improve patient outcomes. For now I will be focusing on the rheumatoid arthritis therapeutic area. If you are familiar with the topic, I would be interested to hear your views.
Martha Uruena
Hi Tom, I think that access must be for everybody. Not only biopharmaceuticals development, biotecnology and obviously genomic test or predictables. We must improve our insight about our own Care, Human Care. Regards!
0 votes
0 thanks
- Badges
- Science topic
- Similar topics
- Econ
- Innovation Economics
- Innovation
Similar questions and discussions